Investment case
Fulcrum Therapeutics, Inc.
FULC · 5 developments mapped · last assessed 2026-09-02
Market Ontology has mapped 5 macro, policy, and market developments to Fulcrum Therapeutics, Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for FULC yet, so no modelled value is shown. The FULC valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run FULC on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Fulcrum Therapeutics, Inc. to Merge with Slate Medicines, Inc.
Direct merger terms, equity dilution, cash dividend, strategic shift, and new pipeline integration.
· Moves future growth rates (revenue, pipeline success), cost of capital (wacc due to perceived risk change), terminal value assumptions (long term competitive position)
What changed, by assumption
- 2026-08-17Fulcrum Therapeutics, Inc. to Merge with Slate Medicines, Inc.
- 2026-08-17Fulcrum Therapeutics, Inc. to Acquire Slate Medicines, Inc.
- 2026-08-17Fulcrum Therapeutics, Inc. Follow-On — $245M
- 2026-08-17Slate Medicines, Inc. Follow-On — $245M
- 2026-09-02Fulcrum Therapeutics, Inc. Files S-4 Registration Statement for Merger
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-17 | Share count | Bullish | The merger involves issuing shares to Slate stockholders and investors in a concurrent investment, significantly increasing the total shares outstanding. | 1.00 |
| 2026-08-17 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-17 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-08-17 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-17 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-17 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-02 | Fulcrum Therapeutics, Inc. Files S-4 Registration Statement for Merger | mixed | 3-12m | 0.60 |
| 2026-08-17 | Fulcrum Therapeutics, Inc. to Acquire Slate Medicines, Inc. | mixed | 1-5y | 0.80 |
| 2026-08-17 | Fulcrum Therapeutics, Inc. Follow-On — $245M | mixed | 1-3m | 0.80 |
| 2026-08-17 | Fulcrum Therapeutics, Inc. to Merge with Slate Medicines, Inc. | mixed | 1-3m | 0.90 |
| 2026-08-17 | Slate Medicines, Inc. Follow-On — $245M | mixed | 1-3m | 0.70 |